Medical insurance reimbursement conditions for ruxolitinib tablets/ruxolitinib

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib), as a targeted therapy drug, has been approved in China and has been included in the scope of medical insurance reimbursement, becoming an important treatment option for patients with some chronic diseases. Ruxolitinib's medical insurance reimbursement coverage covers a variety of diseases, including myelofibrosis (PMF), myelofibrosis secondary to polycythemia vera (PPV-MF), and graft-versus-host disease (GVHD). In China, the original drug ruxolitinib phosphate tablets have been put on the market and have been included in Class B reimbursement of medical insurance.

The medical insurance reimbursement conditions for ruxolitinib are specifically targeted at patients with intermediate-risk or high-risk primary myelofibrosis, especially those who have failed to respond to traditional treatments. The disease in these patients usually progresses quickly and the symptoms are more severe. The use of ruxolitinib can significantly improve the patient's quality of life and slow down the progression of the disease. In addition, ruxolitinib is also indicated for patients with myelofibrosis secondary to polycythemia vera (PPV-MF) or myelofibrosis secondary to essential thrombocythemia (PET-MF), especially those who have failed to respond to glucocorticoids or other treatment options.

In patients with acute graft-versus-host disease (acuteGVHD) or chronic graft-versus-host disease (chronic GVHD), especially those 12 years and older who have an inadequate response to glucocorticoids or other systemic treatments, ruxolitinib is also included in the scope of medical insurance reimbursement. The drug's medical insurance reimbursement conditions cover GVHD patients with higher severity and unsatisfactory treatment results, providing financial support so that patients can obtain more economical and affordable treatment.

As for the drug price of ruxolitinib, the common specifications are20mg*14 tablets and 5mg*60 tablets. The price per box is about 3,000 yuan. Due to the inclusion of medical insurance, patients will be able to enjoy certain cost reimbursement during the treatment process, thereby reducing the patient's financial burden and enabling them to adhere to treatment for a long time.

Reference materials:https://www.jakavi.com/